Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting

Sarah Bartsch, Peter J. Hotez, Daniel L. Hertenstein, David J. Diemert, Kristina M. Zapf, Maria Elena Bottazzi, Jeffrey M. Bethony, Shawn T. Brown, Bruce Lee

Research output: Contribution to journalArticle

Abstract

Background: Although mass drug administration (MDA) has helped reduce morbidity attributed to soil-transmitted helminth infections in children, its limitations for hookworm infection have motivated the development of a human hookworm vaccine to both improve morbidity control and ultimately help block hookworm transmission leading to elimination. However, the potential economic and epidemiologic impact of a preventive vaccine has not been fully evaluated. Methods: We developed a dynamic compartment model coupled to a clinical and economics outcomes model representing both the human and hookworm populations in a high transmission region of Brazil. Experiments simulated different implementation scenarios of MDA and vaccination under varying circumstances. Results: Considering only intervention costs, both annual MDA and vaccination were highly cost-effective (ICERs ≤$790/DALY averted) compared to no intervention, with vaccination resulting in lower incremental cost-effectiveness ratios (ICERs ≤$444/DALY averted). From the societal perspective, vaccination was economically dominant (i.e., less costly and more effective) versus annual MDA in all tested scenarios, except when vaccination was less efficacious (20% efficacy, 5 year duration) and MDA coverage was 75%. Increasing the vaccine's duration of protection and efficacy, and including a booster injection in adulthood all increased the benefits of vaccination (i.e., resulted in lower hookworm prevalence, averted more disability-adjusted life years, and saved more costs). Assuming its target product profile, a pediatric hookworm vaccine drastically decreased hookworm prevalence in children to 14.6% after 20 years, compared to 57.2% with no intervention and 54.1% with MDA. The addition of a booster in adulthood further reduced the overall prevalence from 68.0% to 36.0% and nearly eliminated hookworm infection in children. Conclusion: Using a human hookworm vaccine would be cost-effective and in many cases economically dominant, providing both health benefits and cost-savings. It could become a key technology in effecting control and elimination efforts for hookworm globally.

Original languageEnglish (US)
Pages (from-to)2197-2206
Number of pages10
JournalVaccine
Volume34
Issue number19
DOIs
StatePublished - Apr 27 2016

Fingerprint

Ancylostomatoidea
hookworms
Brazil
Vaccines
Economics
vaccines
drugs
economics
Vaccination
Pharmaceutical Preparations
vaccination
Hookworm Infections
Costs and Cost Analysis
Cost-Benefit Analysis
cost effectiveness
adulthood
morbidity
Economic Models
Morbidity
disability-adjusted life year

Keywords

  • Cost
  • Drug treatment
  • Economics
  • Hookworm
  • Transmission
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting. / Bartsch, Sarah; Hotez, Peter J.; Hertenstein, Daniel L.; Diemert, David J.; Zapf, Kristina M.; Bottazzi, Maria Elena; Bethony, Jeffrey M.; Brown, Shawn T.; Lee, Bruce.

In: Vaccine, Vol. 34, No. 19, 27.04.2016, p. 2197-2206.

Research output: Contribution to journalArticle

Bartsch, Sarah ; Hotez, Peter J. ; Hertenstein, Daniel L. ; Diemert, David J. ; Zapf, Kristina M. ; Bottazzi, Maria Elena ; Bethony, Jeffrey M. ; Brown, Shawn T. ; Lee, Bruce. / Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting. In: Vaccine. 2016 ; Vol. 34, No. 19. pp. 2197-2206.
@article{be196e2b73574634802c2138ff756518,
title = "Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting",
abstract = "Background: Although mass drug administration (MDA) has helped reduce morbidity attributed to soil-transmitted helminth infections in children, its limitations for hookworm infection have motivated the development of a human hookworm vaccine to both improve morbidity control and ultimately help block hookworm transmission leading to elimination. However, the potential economic and epidemiologic impact of a preventive vaccine has not been fully evaluated. Methods: We developed a dynamic compartment model coupled to a clinical and economics outcomes model representing both the human and hookworm populations in a high transmission region of Brazil. Experiments simulated different implementation scenarios of MDA and vaccination under varying circumstances. Results: Considering only intervention costs, both annual MDA and vaccination were highly cost-effective (ICERs ≤$790/DALY averted) compared to no intervention, with vaccination resulting in lower incremental cost-effectiveness ratios (ICERs ≤$444/DALY averted). From the societal perspective, vaccination was economically dominant (i.e., less costly and more effective) versus annual MDA in all tested scenarios, except when vaccination was less efficacious (20{\%} efficacy, 5 year duration) and MDA coverage was 75{\%}. Increasing the vaccine's duration of protection and efficacy, and including a booster injection in adulthood all increased the benefits of vaccination (i.e., resulted in lower hookworm prevalence, averted more disability-adjusted life years, and saved more costs). Assuming its target product profile, a pediatric hookworm vaccine drastically decreased hookworm prevalence in children to 14.6{\%} after 20 years, compared to 57.2{\%} with no intervention and 54.1{\%} with MDA. The addition of a booster in adulthood further reduced the overall prevalence from 68.0{\%} to 36.0{\%} and nearly eliminated hookworm infection in children. Conclusion: Using a human hookworm vaccine would be cost-effective and in many cases economically dominant, providing both health benefits and cost-savings. It could become a key technology in effecting control and elimination efforts for hookworm globally.",
keywords = "Cost, Drug treatment, Economics, Hookworm, Transmission, Vaccine",
author = "Sarah Bartsch and Hotez, {Peter J.} and Hertenstein, {Daniel L.} and Diemert, {David J.} and Zapf, {Kristina M.} and Bottazzi, {Maria Elena} and Bethony, {Jeffrey M.} and Brown, {Shawn T.} and Bruce Lee",
year = "2016",
month = "4",
day = "27",
doi = "10.1016/j.vaccine.2016.03.018",
language = "English (US)",
volume = "34",
pages = "2197--2206",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "19",

}

TY - JOUR

T1 - Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting

AU - Bartsch, Sarah

AU - Hotez, Peter J.

AU - Hertenstein, Daniel L.

AU - Diemert, David J.

AU - Zapf, Kristina M.

AU - Bottazzi, Maria Elena

AU - Bethony, Jeffrey M.

AU - Brown, Shawn T.

AU - Lee, Bruce

PY - 2016/4/27

Y1 - 2016/4/27

N2 - Background: Although mass drug administration (MDA) has helped reduce morbidity attributed to soil-transmitted helminth infections in children, its limitations for hookworm infection have motivated the development of a human hookworm vaccine to both improve morbidity control and ultimately help block hookworm transmission leading to elimination. However, the potential economic and epidemiologic impact of a preventive vaccine has not been fully evaluated. Methods: We developed a dynamic compartment model coupled to a clinical and economics outcomes model representing both the human and hookworm populations in a high transmission region of Brazil. Experiments simulated different implementation scenarios of MDA and vaccination under varying circumstances. Results: Considering only intervention costs, both annual MDA and vaccination were highly cost-effective (ICERs ≤$790/DALY averted) compared to no intervention, with vaccination resulting in lower incremental cost-effectiveness ratios (ICERs ≤$444/DALY averted). From the societal perspective, vaccination was economically dominant (i.e., less costly and more effective) versus annual MDA in all tested scenarios, except when vaccination was less efficacious (20% efficacy, 5 year duration) and MDA coverage was 75%. Increasing the vaccine's duration of protection and efficacy, and including a booster injection in adulthood all increased the benefits of vaccination (i.e., resulted in lower hookworm prevalence, averted more disability-adjusted life years, and saved more costs). Assuming its target product profile, a pediatric hookworm vaccine drastically decreased hookworm prevalence in children to 14.6% after 20 years, compared to 57.2% with no intervention and 54.1% with MDA. The addition of a booster in adulthood further reduced the overall prevalence from 68.0% to 36.0% and nearly eliminated hookworm infection in children. Conclusion: Using a human hookworm vaccine would be cost-effective and in many cases economically dominant, providing both health benefits and cost-savings. It could become a key technology in effecting control and elimination efforts for hookworm globally.

AB - Background: Although mass drug administration (MDA) has helped reduce morbidity attributed to soil-transmitted helminth infections in children, its limitations for hookworm infection have motivated the development of a human hookworm vaccine to both improve morbidity control and ultimately help block hookworm transmission leading to elimination. However, the potential economic and epidemiologic impact of a preventive vaccine has not been fully evaluated. Methods: We developed a dynamic compartment model coupled to a clinical and economics outcomes model representing both the human and hookworm populations in a high transmission region of Brazil. Experiments simulated different implementation scenarios of MDA and vaccination under varying circumstances. Results: Considering only intervention costs, both annual MDA and vaccination were highly cost-effective (ICERs ≤$790/DALY averted) compared to no intervention, with vaccination resulting in lower incremental cost-effectiveness ratios (ICERs ≤$444/DALY averted). From the societal perspective, vaccination was economically dominant (i.e., less costly and more effective) versus annual MDA in all tested scenarios, except when vaccination was less efficacious (20% efficacy, 5 year duration) and MDA coverage was 75%. Increasing the vaccine's duration of protection and efficacy, and including a booster injection in adulthood all increased the benefits of vaccination (i.e., resulted in lower hookworm prevalence, averted more disability-adjusted life years, and saved more costs). Assuming its target product profile, a pediatric hookworm vaccine drastically decreased hookworm prevalence in children to 14.6% after 20 years, compared to 57.2% with no intervention and 54.1% with MDA. The addition of a booster in adulthood further reduced the overall prevalence from 68.0% to 36.0% and nearly eliminated hookworm infection in children. Conclusion: Using a human hookworm vaccine would be cost-effective and in many cases economically dominant, providing both health benefits and cost-savings. It could become a key technology in effecting control and elimination efforts for hookworm globally.

KW - Cost

KW - Drug treatment

KW - Economics

KW - Hookworm

KW - Transmission

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84962592135&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962592135&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2016.03.018

DO - 10.1016/j.vaccine.2016.03.018

M3 - Article

C2 - 27002501

AN - SCOPUS:84962592135

VL - 34

SP - 2197

EP - 2206

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 19

ER -